Company profile: Neurona Therapeutics
1.1 - Company Overview
Company description
- Provider of cell therapies for neurological disorders, including NRTX-1001, a one-time dose therapy for drug-resistant focal epilepsy using human MGE-type inhibitory GABAergic interneurons derived from pluripotent stem cells; myelinating glial cell therapy using human oligodendrocytes to restore myelin; and gene-edited neural cell therapies for targeted delivery to the CNS.
Products and services
- Gene-Edited Neural Cell Therapies: Engineers gene-edited neural cell products for targeted delivery of therapeutic factors to the CNS, overcoming conventional drug delivery barriers
- Myelinating Glial Cell Therapy: Develops pluripotent stem cell-derived human oligodendrocyte therapy to restore myelin and repair the nervous system across various disorders
- NRTX-1001: Produces an MGE-type inhibitory interneuron-based cell therapy using human GABAergic cells derived from pluripotent stem cells for drug-resistant focal epilepsy as a single, one-time dose.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Neurona Therapeutics
Regenicin
HQ: United States
Website
- Description: Provider of regenerative cell therapy development, operating as a biotechnology company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Regenicin company profile →
Clade Therapeutics
HQ: United States
Website
- Description: Provider of scalable, off-the-shelf, next-generation stem-cell-based medicines, discovering and delivering cell medicines to improve patient lives; a biopharmaceutical company incorporated in 2020 and operating in Cambridge, Massachusetts, United States.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Clade Therapeutics company profile →
Vital Therapies
HQ: United States
Website
- Description: Provider of cell-based therapy development for acute liver failure.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vital Therapies company profile →
Sana
HQ: United States
Website
- Description: Provider of engineered cell medicines, offering in vivo and ex vivo cell engineering platforms and hypoimmune allogeneic CAR T therapies using modified healthy donor T cells to evade immune rejection. Pipeline includes SC291 (CD19) for B-cell malignancies and severe B-cell autoimmune diseases, and SC262 (CD22) for B-cell malignancies, all in Phase 1.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sana company profile →
INmune Bio
HQ: United States
Website
- Description: Provider of immune system-based therapies: XPro, a next-generation inhibitor of soluble TNF to decrease neuroinflammation, in clinical trials for Alzheimer's disease and treatment-resistant depression; INKmune, which primes natural killer cells to kill cancer cells, in clinical trials for metastatic castration-resistant prostate cancer; and INB03, neutralizing soluble TNF to down-regulate immune checkpoint proteins in the tumor microenvironment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full INmune Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Neurona Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Neurona Therapeutics
2.2 - Growth funds investing in similar companies to Neurona Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Neurona Therapeutics
4.2 - Public trading comparable groups for Neurona Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →